Combating Resistance To Targeted Anticancer Therapies Via Caspase-3-Mediated MEK Degradation
Increasingly, anticancer drugs targeting mutant or fusion proteins found in a patient’s tumor are becoming the gold standard for modern-day cancer treatment. This personalized approach to oncology has led to dramatic results in the clinic, with potent tumor reduction being observed in a variety of disease traditionally considered recalcitrant to treatment. While these drugs often prove initially effective, acquired resistance invariably occurs and presents as a major limitation and problem in the treatment of cancer. Specifically, many kinase inhibitors have...
Read more